T. Takahashi et al., RECOGNITION OF GP43 TUMOR-ASSOCIATED ANTIGEN PEPTIDE BY BOTH HLA-A2 RESTRICTED CTL LINES AND ANTIBODIES FROM MELANOMA PATIENTS, Cellular immunology, 178(2), 1997, pp. 162-171
Previously, we detected a 43-kDa tumor-associated antigen (TAA) using
the human monoclonal antibody L92, which recognizes the tetramer pepti
de KYQI. In the present study, cell lines of cytotoxic T lymphocytes (
CTL) specific to the gp43 peptide (DLTMKYQIF) were established from pe
ripheral blood lymphocytes (PBL) of melanoma patients. Patients' PBL (
n = 326) of different HLA Class I types were assessed for gp43 CTL act
ivity. CTL specific to gp43 peptide were generated only from HLA-A2 me
lanoma patients and not normal donors. gp3 CTL recognized gp43 peptide
-pulsed autologous BLC and T2 HLA-A2 target cell lines. Furthermore, C
TL lines were shown to kill both HLA-A2 autologous and HLA-A2 allogene
ic melanoma cell lines, indicating that gp43 peptide can be processed
endogenously and presented by melanoma cells as a common TAA. The gp43
CTL lines did not kill normal cells. Specific amino acids of the pept
ide were shown to be important determinants in stimulation and recogni
tion of CTL. gp43 peptide, recognized by both antibodies and T cells o
f melanoma patients, is a novel TAA peptide that may play an important
role in anti-tumor immunity in human. (C) 1997 Academic Press.